文献速递慢性肾脏病遗传性与小管间质肾病

肾脏尿液生物标志物诊断病因不明慢性肾脏病的初步研究

Pilot Study of Renal Urinary Biomarkers for Diagnosis of CKD of Uncertain Etiology.
PubMed 文献 · Kidney Int Rep · 2019-07-24

本研究为横断面研究,纳入病因不明慢性肾脏病(CKDu)、地方性CKD、非地方性CKD及地方性和非地方性健康对照共5组,用多重生物标志物检测法量化8种肾脏尿液标志物。结果发现A1M、KIM1和RBP4三联标志物区分所有CKD类别与健康对照的总体敏感性≥0.867、特异性≥0.765;OPN、KIM1和RBP4组合区分CKDu与CKD的敏感性和特异性均≥0.93,优于现有非侵入性指标。

要点

  • A1M、KIM1和RBP4三联标志物可区分CKD(含CKDu)与健康对照。
  • OPN、KIM1和RBP4组合区分CKDu与CKD的敏感性和特异性均≥0.93。
  • 尿液标志物组合有望用于CKDu的早期无创诊断。

核心结论

  • 尿液标志物组合A1M、KIM1和RBP4可区分所有CKD类别(包括CKDu)与健康对照,总体敏感性≥0.867、特异性≥0.765。
  • OPN、KIM1和RBP4组合区分CKDu与CKD的敏感性和特异性均≥0.93,优于现有非侵入性指标。

研究设计与样本

  • 横断面研究,设5个研究组:CKDu、地方性CKD、非地方性CKD、地方性健康对照和非地方性健康对照。
  • 采用多重生物标志物检测法定量尿液中8种肾脏标志物:NGAL、KIM1、CST3、B2M、OPN、A1M、TIMP1和RBP4。
  • 使用逻辑回归算法系统分析数据,以提取能无创区分疾病组与健康对照的最佳标志物组合。

主要发现

  • A1M、KIM1和RBP4三联标志物是区分所有CKD类别(包括CKDu)与健康对照的最佳最小标志物组合,总体敏感性≥0.867、特异性≥0.765。
  • OPN、KIM1和RBP4组合区分CKDu与CKD的敏感性和特异性均≥0.93,优于任何现有非侵入性指标。

关键数值与推荐

  • A1M、KIM1和RBP4三联面板区分所有CKD类别与健康对照:总体敏感性≥0.867,特异性≥0.765。
  • OPN、KIM1和RBP4组合区分CKDu与CKD:敏感性和特异性均≥0.93。

临床怎么用

  • 尿液A1M、KIM1和RBP4三联检测可作为CKDu早期无创筛查的候选工具。
  • 尿液OPN、KIM1和RBP4组合有助于在CKD患者中鉴别CKDu。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease of uncertain etiology (CKDu), an emerging chronic kidney disease (CKD) subtype, contributes to significant morbidity and mortality in certain tropical countries. Although several indicators of CKDu have been previously suggested, sensitive and specific tests to detect early disease or predict disease progression are currently unavailable. This study focused on evaluating 8 renal urinary markers, namely neutrophil gelatinase-associated lipocalin (NGAL), Kidney Injury Molecule-1 (KIM1), cystatin C (CST3), beta 2 microglobulin (B2M), osteopontin (OPN), alpha 1 microglobulin (A1M), tissue inhibitor of metalloproteinase 1 (TIMP1), and retinol binding protein 4 (RBP4), with the hypothesis that these have distinct expression patterns in patients with CKDu. METHODS: A cross-sectional study was conducted with 5 study groups comprising subjects from CKDu, endemic CKD, nonendemic CKD, and endemic healthy and nonendemic healthy controls. The urinary levels of the 8 selected renal biomarkers were quantified using multiplex biomarker assay, and the data were subjected to systematic analysis using logistic regression algorithm aiming to extract the best marker combination that could distinctly identify the disease groups noninvasively from the healthy controls. RESULTS: A 3-marker signature panel comprising A1M, KIM1, and RBP4 was identified to represent the best minimum marker combination for differentiating all CKD categories, including CKDu, from healthy controls with an overall sensitivity of ≥0.867 and specificity ≥0.765. The marker combination comprising OPN, KIM1, and RBP4 showed high predictive performance for distinguishing patients with CKDu from patients with CKD with both sensitivity and specificity ≥0.93, which was superior to any existing noninvasive indicator. CONCLUSION: In all, our systematic evaluation of urinary markers previously linked to CKD, in general, allowed identification of exclusive marker panel combination for early diagnosis and confirmation of CKDu.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fernando BNTW, Alli-Shaik A, Hemage RKD, et al. Pilot Study of Renal Urinary Biomarkers for Diagnosis of CKD of Uncertain Etiology. Kidney Int Rep. 2019. PMID: 31701049. doi:10.1016/j.ekir.2019.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。